Acetaminophen
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Acetaminophen: Evidence Pack Incomplete — Repurposing Evaluation on Hold
One-Sentence Summary
Acetaminophen (paracetamol, DB00316) is one of the most widely used analgesic and antipyretic agents globally, available in virtually every major market. The current Evidence Pack contains no TxGNN predicted indications for this drug, and the Taiwan regulatory query returned zero records — almost certainly a data retrieval issue rather than true market absence. A full repurposing evaluation cannot be completed until these critical gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no predictions to evaluate) |
| Taiwan Market Status | 未上市（資料品質疑慮，見下方說明） |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
⚠️ Note on Taiwan Market Status: Acetaminophen is a foundational OTC and prescription drug distributed throughout Taiwan under dozens of brand names (e.g., Panadol, Tylenol, and extensive generics). A TFDA query returning 0 results is almost certainly a search parameter mismatch — the TFDA database may index this drug under “Paracetamol”、「乙醯氨酚」、「乙醯胺酚」 or individual brand names. This must be re-queried before any regulatory conclusion is drawn.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack is missing two blocking inputs — TxGNN predicted indications and Taiwan regulatory records — making it impossible to evaluate any repurposing hypothesis, conduct a mechanism analysis, or complete a safety pre-screen. No evaluation sections can be populated in good faith.
To proceed, the following is needed:
- Re-run TFDA query using alternative search terms:
Paracetamol、乙醯氨酚、乙醯胺酚、普拿疼(brand), and wildcard on ingredient field - Resolve TxGNN output gap: Confirm whether the prediction pipeline produced candidates for DB00316; if the model returned no results, document the reason (e.g., drug not present in KG, below score threshold, or pipeline error)
- Retrieve MOA from DrugBank API (DB00316) to support future mechanism analysis
- Download TFDA package insert PDF and extract warnings, contraindications, and special population precautions to clear DG001 (Blocking severity)
- Re-run Evidence Pack generation after above gaps are resolved before proceeding to repurposing evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.